Overview
Alveolar rhabdomyosarcoma (ARMS) is a ligament sarcoma that develops in the body’s soft tissues such as skeleton, tendon, tissue, and joints. Alveolar rhabdomyosarcoma accounts for 25-40 percent of RMS, according to a 2011 survey by Children’s Oncology Group. ARMS is most commonly found in teenagers and affects the arms, legs, chest, and stomach. Alveolar rhabdomyosarcoma has no known origin, although it has been linked to other diseases including Neurofibromatosis type 1, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome, Cardio-facio-cutaneous syndrome, and Costello syndrome. In order to design an appropriate therapy for ARMS, tests such as X-ray imaging, CT scan, MRI, bone scan, ultrasound, PET scan, and a biopsy are used to diagnose the condition. ARMS is a form of high-grade tumor, which means that its cells develop quickly and advance quickly.
Request PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1552
Drivers
The increasing prevalence of alveolar rhabdomyosarcoma, along with technical improvements in radiation therapy, is projected to boost growth of the global alveolar rhabdomyosarcoma treatment market. Soft tissue sarcomas (STS) account for around 7 percent of all malignancies in children and adolescents under the age of 20, according to a 2014 survey by the University of Minnesota, while rhabdomyosarcoma (RMS) accounts for about 40% of pediatric STS. RMS affects 4.5 people each year, with ARMS accounting for 31 percent of cases and the condition being extremely common in 50% of patients under the age of 10.
Furthermore, different government and non-government organizations are pursuing scientific projects to improve the results of alveolar rhabdomyosarcoma as the disorder is linked to poorer mortality rates. Large international cooperative groups, such as the Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG) and the National Comprehensive Cancer Network (NCCN), are conducting medical testing to provide advanced therapies based on the most recent research, which is projected to increase market growth over the forecast period.
Clinical trials are being conducted by organizations and businesses to discover potential treatments for the treatment of pediatric malignancies. Novartis Pharmaceuticals, for example, started a Phase 1 trial for Trametinib in combination with Dabrafenib in children and adolescents with alveolar rhabdomyosarcoma carrying V600 mutations in 2015.
Limited Time Offer Get Flat USD 2000 Off On Purchase
Buy This Premium Report Here: https://www.coherentmarketinsights.com/promo/buynow/1552
Reasons to Purchase this Report
• Current and future of global Alveolar Rhabdomyosarcoma Treatment Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Regional Analysis
During the forecast period, North America is projected to boost the global alveolar rhabdomyosarcoma treatment market, attributable to a growing range of projects initiated by organizations in the region to create therapeutic strategies, increased research and development, and implementation of smart radiation therapies. In 2011, the Doernbecher Children’s Hospital and the Children Oncology Group (COG) facilities in the region started the first molecular targeted therapy in a clinical study for pediatric muscle cancer. The St. Baldrick’s Foundation collaborates with pediatric oncologists and finances supporting cancer research in order to produce promising research that will improve children’s care. The global alveolar rhabdomyosarcoma treatment market in Asia Pacific is anticipated to develop rapidly, owing to increased awareness of the illness in the area, as well as improvements in medical settings that allow for the adoption of innovative therapies.
To Access the Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1552
Competitive Landscape
Major companies contributing in the global alveolar rhabdomyosarcoma treatment market are Bristol-Myers Squibb, Oasmia Pharmaceutical, GlaxoSmithKline Plc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Pfizer, Inc., Boehringer Ingelheim GmbH, Celgene Corporation, and F. Hoffmann-La Roche AG.Johnson & Johnson Services, Inc.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837